Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$1.80
+0.3%
$1.56
$1.05
$5.17
$194.45M0.3979,203 shs328,054 shs
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.59
-6.3%
$1.97
$1.09
$7.22
$183.98M2.971.44 million shs1.06 million shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.04
-0.4%
$7.14
$3.54
$8.90
$163.80M0.8109,590 shs73,754 shs
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.70
+0.3%
$1.67
$0.95
$3.19
$60.79M0.1277,311 shs141,641 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-3.24%+9.15%+11.18%+38.76%+39.84%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-3.50%+23.21%+18.97%+102.94%-56.05%
Journey Medical Corporation stock logo
DERM
Journey Medical
+1.00%-17.21%-1.67%+4.28%+54.70%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-4.52%+10.46%+6.62%-6.63%+15.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
2.7138 of 5 stars
3.63.00.00.02.11.70.6
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
1.4344 of 5 stars
3.22.00.00.01.01.70.0
Journey Medical Corporation stock logo
DERM
Journey Medical
1.5269 of 5 stars
3.31.00.00.01.60.80.6
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2.2355 of 5 stars
3.53.00.00.02.30.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$8.71385.48% Upside
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.33
Hold$8.00209.48% Upside
Journey Medical Corporation stock logo
DERM
Journey Medical
2.50
Moderate Buy$10.8353.88% Upside
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3.00
Buy$7.80360.18% Upside

Current Analyst Ratings Breakdown

Latest GANX, CCCC, ACRS, and DERM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/13/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $13.00
8/13/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $6.00
7/10/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$6.00
7/3/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/25/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/23/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
5/28/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$8.00
(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$18.72M10.39N/AN/A$1.22 per share1.47
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$34.24M5.37N/AN/A$2.45 per share1.06
Journey Medical Corporation stock logo
DERM
Journey Medical
$56.13M2.92N/AN/A$0.83 per share8.48
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/A$0.10 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$132.07M-$1.37N/AN/AN/A-802.03%-34.01%-24.18%11/5/2025 (Estimated)
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)
Journey Medical Corporation stock logo
DERM
Journey Medical
-$14.67M-$0.38N/AN/AN/A-15.49%-48.69%-11.26%N/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$20.41M-$0.63N/AN/AN/AN/A-289.10%-155.11%N/A

Latest GANX, CCCC, ACRS, and DERM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million
8/12/2025Q2 2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.17-$0.19-$0.02-$0.19N/AN/A
8/7/2025Q2 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.13-$0.13N/A-$0.13$1.34 million$1.78 million
8/7/2025Q2 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
3.88
3.88
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.06
5.06
Journey Medical Corporation stock logo
DERM
Journey Medical
1.11
1.27
0.95
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.09
1.79
1.79

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%

Insider Ownership

CompanyInsider Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
5.60%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.73%
Journey Medical Corporation stock logo
DERM
Journey Medical
15.03%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
7.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100108.33 million102.27 millionOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.17 million64.96 millionOptionable
Journey Medical Corporation stock logo
DERM
Journey Medical
9023.30 million19.80 millionN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2035.95 million33.37 millionOptionable

Recent News About These Companies

Roth Capital Analysts Increase Earnings Estimates for GANX
Equities Analysts Offer Predictions for GANX Q3 Earnings
Gain Therapeutics Announces Proposed Public Offering
Gain Therapeutics (GANX) Gets a Buy from Scotiabank

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$1.80 +0.01 (+0.28%)
As of 02:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$2.58 -0.18 (-6.34%)
As of 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.04 -0.03 (-0.42%)
As of 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.70 +0.01 (+0.30%)
As of 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.